Cash figures as of 2026-03-31. Database snapshot: 2026-09-22.
Price history
Loading SHPH daily closes…
Loading price history…
Pipeline assets
Ropidoxuridine
Stage not disclosed · Terminated
Indications
not disclosed(Stage not disclosed)
Status note Former lead product candidate; on November 20, 2025 the company committed to a plan to wind down its clinical trials of Ropidoxuridine. Company has pivoted to the Molecule.ai AI-driven drug discovery platform (acquired November 2025).
Per-asset detail extracted from the 10-Q filed 2026-05-15. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.